{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T09:10:58Z","timestamp":1790413858909,"version":"4.1.0"},"reference-count":15,"publisher":"American Society of Hematology","issue":"12","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2018,6,26]]},"abstract":"<jats:title>Key Points<\/jats:title>\n                  <jats:p>This trial evaluates addition of the histone deacetylase inhibitor valproate to standard R-CHOP therapy in DLBCL. Addition of valproate to R-CHOP is a promising strategy in DLBCL, but auditory side effects warrant monitoring.<\/jats:p>","DOI":"10.1182\/bloodadvances.2018019240","type":"journal-article","created":{"date-parts":[[2018,6,14]],"date-time":"2018-06-14T11:55:27Z","timestamp":1528977327000},"page":"1386-1392","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":29,"title":["Valproate in combination with rituximab and CHOP as first-line therapy in diffuse large B-cell lymphoma (VALFRID)"],"prefix":"10.1182","volume":"2","author":[{"given":"Kristina","family":"Drott","sequence":"first","affiliation":[{"name":"Department of Oncology, Sk\u00e5ne University Hospital, Lund, Sweden;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans","family":"Hagberg","sequence":"additional","affiliation":[{"name":"Department of Oncology, Akademiska, Uppsala University Hospital, Uppsala, Sweden; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Papworth","sequence":"additional","affiliation":[{"name":"Department of Oncology, Norrland University Hospital, Ume\u00e5, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Relander","sequence":"additional","affiliation":[{"name":"Department of Oncology, Sk\u00e5ne University Hospital, Lund, Sweden;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mats","family":"Jerkeman","sequence":"additional","affiliation":[{"name":"Department of Oncology, Sk\u00e5ne University Hospital, Lund, Sweden;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2018,6,14]]},"reference":[{"key":"2019111616434821700_B1","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1186\/s12943-015-0474-2","article-title":"Novel drug targets for personalized precision medicine in relapsed\/refractory diffuse large B-cell lymphoma: a comprehensive review","volume":"14","author":"Camicia","year":"2015","journal-title":"Mol Cancer"},{"issue":"9","key":"2019111616434821700_B2","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1038\/ng.892","article-title":"Analysis of the coding genome of diffuse large B-cell lymphoma","volume":"43","author":"Pasqualucci","year":"2011","journal-title":"Nat Genet"},{"issue":"7337","key":"2019111616434821700_B3","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/nature09730","article-title":"Inactivating mutations of acetyltransferase genes in B-cell lymphoma","volume":"471","author":"Pasqualucci","year":"2011","journal-title":"Nature"},{"key":"2019111616434821700_B4","first-page":"479364","article-title":"Molecular and therapeutic potential and toxicity of valproic acid","volume-title":"J Biomed Biotechnol.","author":"Chateauvieux","year":"2010"},{"issue":"9","key":"2019111616434821700_B5","doi-asserted-by":"crossref","first-page":"3815","DOI":"10.1158\/0008-5472.CAN-04-2478","article-title":"Valproic acid alters chromatin structure by regulation of chromatin modulation proteins","volume":"65","author":"Marchion","year":"2005","journal-title":"Cancer Res"},{"issue":"23","key":"2019111616434821700_B6","doi-asserted-by":"crossref","first-page":"8467","DOI":"10.1158\/1078-0432.CCR-05-1073","article-title":"Synergistic interaction between histone deacetylase and topoisomerase II inhibitors is mediated through topoisomerase IIbeta","volume":"11","author":"Marchion","year":"2005","journal-title":"Clin Cancer Res"},{"issue":"2","key":"2019111616434821700_B7","first-page":"170","article-title":"The histone deacetylase inhibitor valproic acid sensitizes diffuse large B-cell lymphoma cell lines to CHOP-induced cell death","volume":"5","author":"Ageberg","year":"2013","journal-title":"Am J Transl Res"},{"issue":"10","key":"2019111616434821700_B8","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1038\/leu.2010.157","article-title":"HDAC inhibitors augment cytotoxic activity of rituximab by upregulating CD20 expression on lymphoma cells","volume":"24","author":"Shimizu","year":"2010","journal-title":"Leukemia"},{"key":"2019111616434821700_B9","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/2162-3619-4-4","article-title":"Pharmacologically relevant doses of valproate upregulate CD20 expression in three diffuse large B-cell lymphoma patients in vivo","volume":"4","author":"Damm","year":"2015","journal-title":"Exp Hematol Oncol"},{"issue":"5","key":"2019111616434821700_B10","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","article-title":"Revised response criteria for malignant lymphoma","volume":"25","author":"Cheson","year":"2007","journal-title":"J Clin Oncol"},{"issue":"10","key":"2019111616434821700_B11","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.3109\/10428194.2011.587560","article-title":"Marked improvement of overall survival in mantle cell lymphoma: a population based study from the Swedish Lymphoma Registry","volume":"52","author":"Abrahamsson","year":"2011","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"2019111616434821700_B12","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1093\/pan\/mpl013","article-title":"Matching as nonparametric preprocessing for reducing model dependence in parametric causal inference","volume":"15","author":"Ho","year":"2007","journal-title":"Polit Anal"},{"issue":"7","key":"2019111616434821700_B13","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.1158\/1078-0432.CCR-08-1930","article-title":"Clinical and biological effects of valproic acid as a histone deacetylase inhibitor on tumor and surrogate tissues: phase I\/II trial of valproic acid and epirubicin\/FEC","volume":"15","author":"Munster","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"10","key":"2019111616434821700_B14","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1200\/JCO.2013.51.5866","article-title":"Event-free survival at 24 months is a robust end point for disease-related outcome in diffuse large B-cell lymphoma treated with immunochemotherapy","volume":"32","author":"Maurer","year":"2014","journal-title":"J Clin Oncol"},{"issue":"4","key":"2019111616434821700_B15","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1002\/ajh.25010","article-title":"A phase I\/II trial of vorinostat (SAHA) in combination with rituximab-CHOP in patients with newly diagnosed advanced stage diffuse large B-cell lymphoma (DLBCL): SWOG S0806","volume":"93","author":"Persky","year":"2018","journal-title":"Am J Hematol"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/2\/12\/1386\/881203\/advances019240.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/2\/12\/1386\/881203\/advances019240.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,16]],"date-time":"2019-11-16T16:44:01Z","timestamp":1573922641000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/2\/12\/1386\/15914\/Valproate-in-combination-with-rituximab-and-CHOP"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,14]]},"references-count":15,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2018,6,26]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2018019240","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6,14]]}}}